AKT3 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NB100-1480
Key Product Details
Species Reactivity
Validated:
Human, Mouse, Rat
Predicted:
Bovine (100%), Canine (100%). Backed by our 100% Guarantee.
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Peptide ELISA, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Peptide with sequence CSPTSQIDNIGEEEM corresponding to internal region according to NP_005456.1, NP_859029.1.
Specificity
This antibody is expected to recognise an epitope corresponding to aa 119-133 of both isoforms of human AKT3 protein. This antibody does not cross-react with human AKT1/2. Reported variants represent identical protein (NP_859029.1; NP_001193658.1).
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for AKT3 Antibody
Western Blot: AKT3 Antibody [NB100-1480]
Western Blot: AKT3 Antibody [NB100-1480] - staining of HepG2 (A), Jurkat (B), Mouse Brain (C) and Rat Brain (D) lysates (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.Immunohistochemistry-Paraffin: AKT3 Antibody [NB100-1480]
Immunohistochemistry-Paraffin: AKT3 Antibody [NB100-1480] - staining of paraffin embedded Human Prostate. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.Western Blot: AKT3 Antibody [NB100-1480]
Western Blot: AKT3 Antibody [NB100-1480] - (1ug/ml) staining of HepG2lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.Applications for AKT3 Antibody
Application
Recommended Usage
Immunohistochemistry-Paraffin
5 ug/ml
Peptide ELISA
Detection limit 1:16000
Western Blot
1 - 3 ug/ml
Application Notes
WB: A 50-55 kDa band observed in HepG2 and Jurkat lysates and in mouse and rat brain lysates (calculated MW of 54.0 kDa band according to NP_859029.1
IHC: Paraffin embedded Human Prostate and Heart.
IHC: Paraffin embedded Human Prostate and Heart.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: Akt3
The main function of AKT is to control inhibition of apoptosis and promote cell proliferation. Survival factors can activate AKT Ser473 and Thr308 phosphorylation sites in a transcription-independent manner, resulting in the inactivation of apoptotic signaling transduction through the tumor suppressor PTEN, an antagonist to PI3-K (5). PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP3) phosphatase, opposing PI3K activity by decreasing availability of PIP3 to proliferating cells, leading to overexpression and inappropriate activation of AKT noted in many types of cancer.
AKT1 function has been linked to overall physiological growth and function (2). AKT1 has been correlated with proteus syndrome, a rare disorder characterized by overgrowth of various tissues caused by a mosaic variant in the AKT1 gene in humans.
AKT2 is strongly correlated with Type II diabetes, including phenotypes of insulin resistance, hyperglycemia and atherosclerosis (2, 6).
The function of AKT3 is specifically associated to brain development, where disruptions to AKT3 are correlated with microcephaly, hemimegalencephaly, megalencephaly and intellectual disabilities (2).
References
1. Ersahin, T., Tuncbag, N., & Cetin-Atalay, R. (2015). The PI3K/AKT/mTOR interactive pathway. Mol Biosyst, 11(7), 1946-1954. doi:10.1039/c5mb00101c
2. Cohen, M. M., Jr. (2013). The AKT genes and their roles in various disorders. Am J Med Genet A, 161a(12), 2931-2937. doi:10.1002/ajmg.a.36101
3. Georgescu, M. M. (2010). PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer, 1(12), 1170-1177. doi:10.1177/1947601911407325
4. Mishra, P., Paital, B., Jena, S., Swain, S. S., Kumar, S., Yadav, M. K., . . . Samanta, L. (2019). Possible activation of NRF2 by Vitamin E/Curcumin against altered thyroid hormone induced oxidative stress via NFkB/AKT/mTOR/KEAP1 signalling in rat heart. Sci Rep, 9(1), 7408. doi:10.1038/s41598-019-43320-5
5. Wedel, S., Hudak, L., Seibel, J. M., Juengel, E., Oppermann, E., Haferkamp, A., & Blaheta, R. A. (2011). Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. Prostate, 71(7), 722-735. doi:10.1002/pros.21288
6. Rotllan, N., Chamorro-Jorganes, A., Araldi, E., Wanschel, A. C., Aryal, B., Aranda, J. F., . . . Fernandez-Hernando, C. (2015). Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis. Faseb j, 29(2), 597-610. doi:10.1096/fj.14-262097
Long Name
v-Akt Murine Thymoma Viral Oncogene Homolog 3
Alternate Names
PKB gamma, RAC-gamma
Entrez Gene IDs
10000 (Human)
Gene Symbol
AKT3
UniProt
Additional Akt3 Products
Product Documents for AKT3 Antibody
Product Specific Notices for AKT3 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...